Tesla's India play: Niche appeal now, bigger potential later
"While the premium electric car segment remains niche, it is growing rapidly, driven by India's rising millionaire population and their appetite for high-tech vehicles," said Puneet Gupta, Director of India & ASEAN Auto Market at S&P Global Mobility.
Industry data shows luxury EV sales surged 66% year-on-year between January and May 2025. These vehicles now account for 11% of total luxury car sales, up from 7% in the same period last year.
Gupta suggests Tesla could explore setting up a manufacturing plant in India within 2-3 years, as rising passenger vehicle exports and shifting domestic demand may incentivize the automaker to develop India-specific models.
He also highlighted the timing of Tesla's strategy to initially sell cars as completely built units (CBUs) and potential benefits from ongoing India-US trade negotiations. "If the trade agreement reduces import taxes on American cars, Tesla could see a major price advantage, boosting its sales significantly," Gupta added.
Vinay Raghunath, Partner, Automotive and Mobility Sector Leader at EY India, said that while the initial impact of Tesla's entry may be more symbolic, it will undoubtedly elevate consumer awareness, spark greater interest in EVs and set new benchmarks in connected and autonomous mobility.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 minutes ago
- Economic Times
Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel "The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get disentangled," says Sudip Bandyopadhyay , Group Chairman, Inditrade Capital Well, of course, what has changed significantly is the tariff announcement by President Trump. There was a sword hanging on pharma sector and at different levels different figures were being thrown around. But finally, when the announcement came, it talks about very high 200% or whatever but it is after two obviously people immediately started talking about the fact that probably it will never come because if something gets pushed back by two years obviously there is no threat of imminent tariff on pharma products, so that was a fantastic news for most Indian pharma companies because most of them or at least a lot of them have significant business in do manufacture in India and supply to US, so they would have been adversely affected by the tariff and since that is not happening, that was the point from where pharma actually we started seeing significant momentum in largecap and some midcap pharma companies. As far as overall pharma is concerned Sun Pharma does look good because some of the molecules which they were expected to commercialise a bit later in the year is getting preponed and the commercial launch is happening in US very-very soon and that kind of enthused the investors about Sun they have significant business in US as well as India and both the markets are expected to do good. The pricing pressure on generics is, of course, there but that has kind of reached a level where we have seen the course, Glenmark did a landmark deal and it is not only for Glenmark, for the entire Indian pharmaceutical industry this was a landmark deal with R&D getting established and getting properly valued by global pharma players, so this was definitely landmark and of course, Glenmark investors were rewarded and will be rewarded further I am sure in terms of dividend or other some kind of payouts, so that is as far as Glenmark and Sun Pharma is by and large Indian pharma can breathe a sigh of relief post the tariffs sword going away and it is back to business as usual and considering that most of the sectors are kind of still awaiting to know about the tariff and its implications, pharma is one sector where that has been taken care of. Hence, pharma is rallying, that is my it is definitely positive for the overall steel industry. We have to remember that globally also demand for steel is going up and naturally price hike in the domestic scenario is also expected. The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get is very critical for JSW Steel at this stage. Of course, coking coal prices of the entire industry will be interesting to understands the trend and what the management commentary is for multiple companies not only JSW Steel because that is a very-very critical ingredient as far as steel making is and large, we believe that the industry margins would have improved in this current quarter for which results will come out. Top line depends on company specific like JSW Steel had a scheduled maintenance, so obviously the volume will be low, but the margin improvement will be visible.
Mint
9 minutes ago
- Mint
Stocks to buy: Rajesh Palviya of Axis Sec suggests Torrent Pharma, Prestige Estates, V-Guard shares today
Stock market today: The Indian stock market started off flat on Friday as ongoing weak investor sentiment persisted due to continued selling by Foreign Portfolio Investors (FPIs) and a lackluster earnings season in the IT sector. The Nifty 50 index commenced at 25,108.55, experiencing a slight decline of 2.90 points or 0.01 percent. At the same time, the BSE Sensex opened the session at 82,193.62, dropping by 65.62 points or 0.08 percent. Analysts attributed the market's weak opening to the current disappointing earnings reports. On the technical front, Rajesh Palviya of Axis Securities, believes Nifty 50's short-term outlook remains cautious with expected upside of 25,400-25,500 levels. Palviya recommends three stocks to buy. Here's what he says about the overall market. On the daily and hourly charts, the index is trending lower, forming a series of lower tops and bottoms, indicating negative bias. Nifty 50 is sustaining below its 20-day SMA, which signals a short-term downtrend. From current levels, the short-term outlook remains cautious with expected upside of 25,400-25,500 levels. On the downside, the short-term supports are placed around 25,000-24,900 levels. The daily strength indicator RSI has turned bearish and sustained below its reference lines, indicating a loss of strength. On the daily and weekly charts, the stock has experienced continuation of the prior uptrend, forming a series of higher tops and bottoms. In addition, the weekly prices have also confirmed a "down-sloping trendline" breakout at 3,400 levels, which signals a strong comeback of bulls. The past 3-4 weeks' rising volumes signify increased participation. The stock is sustaining above its 20, 50, 100 and 200-day Simple Moving Averages (SMA), reconfirming the bullish trend. The daily and weekly strength indicator, Relative Strength Index (RSI), is in favourable territory, indicating rising strength across all time frames. Investors should consider buying, holding, and accumulating this stock. Its expected upside is ₹ 3,700-3,950, and its downside support zone is the 3,450-3,400 levels. On the daily chart, the stock has confirmed a "multiple resistance zone" of 1760 levels on a closing basis, which shows bullish sentiments. Huge rising volumes on breakout signify increased participation. The daily "band bollinger" buy signal indicates increased momentum. The stock is sustaining above its 20, 50, 100 and 200-day Simple Moving Averages (SMA), reconfirming the bullish trend. The daily and weekly strength indicator, Relative Strength Index (RSI), is in favourable territory, indicating rising strength across all time frames. Investors should consider buying, holding, and accumulating this stock. Its expected upside is ₹ 1,900-1,950, and its downside support zone is the 1,720-1,700 levels. On the daily chart, the stock has surpassed the 5-6 months multiple resistance zone of 400 levels on a closing basis. Huge rising volumes on breakout signify increased participation. The stock is sustaining above its 20, 50, 100 and 200-day Simple Moving Averages (SMA), reconfirming the bullish trend. The daily and weekly strength indicator, Relative Strength Index (RSI), is in favourable territory, indicating rising strength across all time frames. Investors should consider buying, holding, and accumulating this stock. Its expected upside is ₹ 430-450, and its downside support zone is the 390-385 levels. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
9 minutes ago
- Economic Times
Missing the data bus? India must act fast, says top statistician
ETtech Representative Image A senior Indian statistician has called for enhanced data-sharing between institutions and the central government, including access to mobile payments and official records, to boost the accuracy and reliability of key economic indicators. Rajeeva Laxman Karandikar, chairman of the National Statistical Commission, the top advisory body to the Ministry of Statistics and Programme Implementation, said many organisations, from banks and payment firms to transport services and even government departments such as tax and railways, are hesitant to share data. The reluctance, he noted in an interview reported by Bloomberg, stems from privacy and legal concerns. 'But high-level policy decisions need to be taken as to what can be shared,' he said. Talks are currently underway to enable sharing of masked or aggregated data based on area codes, a move Karandikar said could significantly improve data accuracy, although discussions remain in early India's economy continues to grow and attract global investor attention, official economic data is under increasing scrutiny. There is a growing demand for more accurate indicators that reflect real conditions on the ground and help policymakers design better-informed strategies to meet the country's evolving data sharing between government departments remains difficult due to administrative gaps, infrastructure limitations, and ongoing concerns about data protection. These challenges make it difficult to strike a balance between transparency and privacy. To address these issues, the government has recently taken several steps. These include plans to conduct the long-pending population census, publishing monthly labour data, and releasing more frequent surveys to strengthen economic indicators such as inflation and said many developed nations have already created effective systems to internally share relevant data. 'India has not done that fast enough. We need to move in that direction,' he National Statistical Commission has also recommended that the government speed up the release of official statistics. Karandikar believes that wider use of digital tools and greater access to existing data would help reduce delays. 'Unless we change and bring in this information technology infrastructure, we will become obsolete,' he further stressed the need to replace long, annual surveys with shorter, quicker ones to make data collection and processing more efficient. 'The old methodology of data collection, transmitting, compiling and processing has to change,' Karandikar said, noting that the government has already started implementing some of these improvements. With inputs from Bloomberg
